Cosmo makes significant progress in 2016
(WorldNews Netherlands)

Cosmo makes significant progress in 2016 Two successful phase III clinical trials Increased operating revenues on lower cost base with EUR 27.5 million pre-tax profit in 2016 Proposal for a dividend increased to EUR 1.50 per share Confident outlook for 2017, significant investments in the US Dublin - March 24, 2017- Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced its results for the year ended 31 December 2016. Financial highlights Operating revenues increased by 11.6% to EUR 67.7 million. Increase in personnel by 8%, operating costs down by 34.8% to EUR 43.0 million because of decrease in management bonus. Profit after tax of EUR 19.3 million (2015 results were primarily driven by the EUR...